Medical Device Entrepreneurship Elevator Pitch Event

Newborn babies in the neonatal intensive care unit need blood taken from the heel to detect a number of serious diseases. Our non-invasive, continuous monitoring device reveals detrimental fluctuations in the patient’s vitals, allowing us to eliminate the need for invasive newborn testing altogether. The introduction of this technology to the healthcare industry would improve hospital efficiency and most importantly, reduce the negative physical and psychological implications on families while their newborn is in intensive care.

Bleeding is the leading cause of preventable death after traumatic injury. We are developing advanced wound dressings incorporating a superhydrophobic haemostatic material to control bleeding. Our technology accelerates clotting while also mitigating wound adhesion and secondary bleeding. We are initially targeting medical professionals in prehospital and emergency care settings in the United States.

Our diagnostic device draws conclusions based on the blood sample's physicochemical properties by using spectroscopy and pattern recognition. It will be easily integrated into doctors' offices and hospitals, drastically reducing the time to diagnose multiple sclerosis.

Our team is building smart wristbands to detect hand gestures in virtual reality, enabling users to interact naturally with their surroundings. Our device will make VR/AR games more immersive and unlock new applications in healthcare, education and defense.

Our device is a handheld breath analyser that is capable of measuring lactate levels. Our objective is to utilise this device as a pre-hospital point-of-care diagnostic tool for stratifying sepsis severity, enabling early intervention while potentially saving lives and resources.

About 100,000 fractures will become nonunion in the United States each year, affecting people of all ages and severely limiting their ability work. Our technology uses a patented technology to deliver growth factors to the region while minimizing the spread to other areas.

Our pharmaceutical treatment hinders collagen overproduction in scleroderma by targeting a small molecule within the disease pathway. It is the first targeted treatment to restore immune system balance in scleroderma patients.

We have developed wireless, miniaturised, MRI-safe sensors known as brain computer interfaces that are able to pick up electrical signals from precise regions in the brain and bypass neurological injury. Our technology has the potential to treat a wide range of neurological conditions and restore motor and sensory functions. The initial aim of our technology is to help patients with paralysis so they may regain their independence.

In open heart surgeries, surgeons cut the patient’s chest (sternal) bone to reach the heart and sew it with sternal wires at the end of the surgery. Sternal infection is a post-operative complication that is complex to treat, mainly because it is diagnosed late. Our technology allows early detection of infections through embedded sensors in sternal wires, allowing quick medical intervention.

Our device is a handheld breath analyser that is capable of measuring lactate levels. Our objective is to utilise this device as a pre-hospital point-of-care diagnostic tool for stratifying sepsis severity, enabling early intervention while potentially saving lives and resources.